Jun 05, 2023 / 12:00PM GMT
Presentation
Jun 05, 2023 / 12:00PM GMT
=====================
Corporate Participants
=====================
* Aleix Prat
Oncolytics Biotech Inc. - Member of Scientific Advisory Board
* Matthew C. Coffey
Oncolytics Biotech Inc. - President, CEO & Director
* Richard Vile
Oncolytics Biotech Inc. - Member of Scientific Advisory Board
* Thomas C. Heineman
Oncolytics Biotech Inc. - Chief Medical Officer
=====================
Conference Call Participants
=====================
* John Lawrence Newman
Canaccord Genuity Corp., Research Division - Principal & Senior Healthcare Analyst
* Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD
* Patrick Ralph Trucchio
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
* Soumit Roy
JonesTrading Institutional Services, LLC, Research Division - Director & Healthcare Analyst
* Martine J. Piccart
Oncolytics Biotech Inc
(TSX:ONC)
C$
1.55
0.06 (4.03%)
Market Cap: 119.13 Mil
Enterprise Value: 95.39 Mil
PE Ratio: 0
PB Ratio: 6.51
GF Score: 38/100 Oncolytics Biotech Inc To Discuss Data from the Randomized Phase 2 BRACELET-1 Trial in HR+/HER2 Presentation Transcript
Jun 05, 2023 / 12:00PM GMT
Release Date Price:
C$2.15
(-5.70%)
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot